What Did This CEO Just Do with Personal Shares of Amphastar Pharmaceuticals (AMPH)?


Yesterday, the CEO & Chief Scientific Officer of Amphastar Pharmaceuticals (AMPH), Jack Zhang, sold shares of AMPH for $892K.

In addition to Jack Zhang, 10 other AMPH executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Amphastar Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $75.54 million and quarterly net profit of $2.39 million. In comparison, last year the company earned revenue of $57.92 million and had a net profit of $175K. Currently, Amphastar Pharmaceuticals has an average volume of 303.1K.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $24.00, reflecting a 19.8% upside.

The insider sentiment on Amphastar Pharmaceuticals has been negative according to 59 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Jack Zhang’s trades have generated a 12.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts